|
Hydroxychloroquine, n (%)
|
321 (51.8)
|
15 (42.9)
|
127 (75.6)
|
99 (60.4)
|
59 (47.2)
|
17 (18.1)
|
4 (11.8)
|
< 0.001
|
|
Remdesivir, n (%)
|
109 (17.6)
|
4 (11.4)
|
31 (18.5)
|
33 (20.1)
|
11 (8.8)
|
24 (25.5)
|
6 (17.6)
|
0.029
|
|
Tocilizumab, n (%)
|
88 (14.2)
|
1 (2.9)
|
22 (13.1)
|
27 (16.5)
|
23 (18.4)
|
11 (11.7)
|
4 (11.8)
|
0.220
|
|
Dexamethasone, n (%)
|
28 (4.5)
|
0 (0.0)
|
10 (6.0)
|
6 (3.7)
|
7 (5.6)
|
4 (4.3)
|
1 (2.9)
|
0.655
|
|
Room air, n (%)
|
507 (81.8)
|
31 (88.6)
|
145 (86.3)
|
133 (81.1)
|
95 (76.0)
|
75 (79.8)
|
28 (82.4)
|
0.260
|
|
Nasal cannula, n (%)
|
529 (85.3)
|
32 (91.4)
|
150 (89.3)
|
141 (86.0)
|
103 (82.4)
|
75 (79.8)
|
28 (82.4)
|
0.252
|
|
Mask, n (%)
|
411 (66.3)
|
25 (71.4)
|
119 (70.8)
|
105 (64.0)
|
79 (63.2)
|
60 (63.8)
|
23 (67.6)
|
0.676
|
|
Continuous positive airway pressure (CPAP), n (%)
|
78 (12.6)
|
6 (17.1)
|
22 (13.1)
|
23 (14.0)
|
13 (10.4)
|
12 (12.8)
|
2 (5.9)
|
0.709
|
|
Bi-level positive airway pressure (BIPAP), n (%)
|
87 (14.0)
|
4 (11.4)
|
24 (14.3)
|
16 (9.8)
|
20 (16.0)
|
17 (18.1)
|
6 (17.6)
|
0.448
|
|
High-flow nasal cannula, n (%)
|
296 (47.7)
|
10 (28.6)
|
56 (33.3)
|
86 (52.4)
|
76 (60.8)
|
50 (53.2)
|
18 (52.9)
|
< 0.001
|
|
Invasive mechanical ventilation, n (%)
|
371 (59.8)
|
23 (65.7)
|
131 (78.0)
|
98 (59.8)
|
65 (52.0)
|
40 (42.6)
|
14 (41.2)
|
< 0.001
|
|
Prone ventilation, n (%)
|
356 (57.4)
|
16 (45.7)
|
97 (57.7)
|
97 (59.1)
|
87 (69.6)
|
47 (50.0)
|
12 (35.3)
|
0.002
|
|
Duration of invasive mechanical ventilation (days), median (IQR)
|
9.1 (4.7–14.4)
|
8.6 (3.5–17.0)
|
9.9 (7.0–15.4)
|
7.4 (4.1–12.1)
|
8.9 (3.9–15.9)
|
8.7 (4.0–15.7)
|
3.9 (2.5–9.6)
|
0.018
|
|
ICU length of stay (LOS) (days), median (IQR)
|
6.2 (2.7–12.5)
|
4.8 (3.4–13.7)
|
9.1 (3.5–13.6)
|
6.0 (2.5–11.4)
|
6.2 (2.3–14.1)
|
5.0 (2.6–9.1)
|
4.0 (1.5–7.4)
|
0.004
|
|
Hospital LOS (days), median (IQR)
|
12.7 (7.5–21.8)
|
10.7 (7.1–28.4)
|
14.1 (8.1–23.0)
|
13.6 (8.3–22.1)
|
13.4 (7.2–21.6)
|
10.0 (5.9–17.02)
|
8.7 (5.5–16.1)
|
0.009
|
